NCT06697600 A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
| NCT ID | NCT06697600 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Rochester |
| Condition | Oncology |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,020 participants |
| Start Date | 2025-07-11 |
| Primary Completion | 2029-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,020 participants in total. It began in 2025-07-11 with a primary completion date of 2029-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multicenter randomized controlled trial that assesses the efficacy of a decisional intervention \[University of Rochester-Geriatric Oncology assessment for Acute myeloid Leukemia (UR-GOAL)\] compared to an attention control.
Eligibility Criteria
Patients Inclusion criteria: * Age ≥60 years (from date of consent, confirmed on electronic medical records) * A new diagnosis of AML * Diagnosis can be based on the International Consensus Classification or World Health Organization * Myeloid sarcoma is allowed * AML with central nervous system involvement is allowed * Cancer-directed treatment has not started * Treatment to temporarily decrease white blood cells is acceptable; these may include hydroxyurea, leukapheresis, or cytarabine * Intrathecal chemotherapy is acceptable * The patient's oncologist has been or will be enrolled on the study * English or Spanish-speaking * Patients without a caregiver will still be eligible to participate in the study Exclusion criteria * A diagnosis of acute promyelocytic leukemia * Patients with psychiatric or cognitive conditions which the treating oncologist believes prohibits informed consent or compliance with study procedures * Prior cancer-directed treatment for AML Caregivers Inclusion criteria: * Selected by the patient when asked if there is a "family member, partner, friend or caregiver \[age 18 or older\] with whom you discuss or who can be helpful in healthrelated matters." * Caregiver may be paid/professional or informal caregiver * Able to provide informed consent * English or Spanish-speaking Oncologists Inclusion criteria: • Oncologists caring for patients with AML Exclusion criteria
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06697600 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Oncology. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06697600 currently recruiting?
Yes, NCT06697600 is actively recruiting participants. Contact the research team at Kahpoh_Loh@URMC.Rochester.edu for enrollment information.
Where is the NCT06697600 trial being conducted?
This trial is being conducted at Birmingham, United States, Rochester, United States, Chapel Hill, United States, Winston-Salem, United States.
Who is sponsoring the NCT06697600 clinical trial?
NCT06697600 is sponsored by University of Rochester. The trial plans to enroll 1,020 participants.